Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

scharper s.p.a. - budesonide - budesonide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

dr. falk pharma gmbh - budesonide - budesonide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

idi farmaceutici s.r.l. - budesonide - budesonide

Unione Europea - italiano - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - farmaci per le malattie respiratorie ostruttive, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Unione Europea - italiano - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - farmaci per le malattie respiratorie ostruttive, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Unione Europea - italiano - EMA (European Medicines Agency)

dr. falk pharma gmbh - budesonide - malattie esofagee - antidiarrheals, intestinali antiinfiammatori / antinfettivo agenti - jorveza è indicato per il trattamento della esofagite eosinofila (eoe) negli adulti (di età superiore a 18 anni).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - budesonidum - zäpfchen - budesonidum 4 mg, e 304, adeps solidus, pro suppositorio. - behandlung der leichten bis mittelschweren akuten colitis ulcerosa, die auf den enddarm beschränkt ist (proktitis). - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum - turbuhaler - budesonidum 100 µg pro dosi, dosi pro vaso 200. - la rinite - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum - pumpspray - budesonidum 32 µg mantenuto.: e 202, excipiens annuncio suspensionem pro dosi. dosi pro vaso 120. - la rinite - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum - pumpspray - budesonidum 64 µg mantenuto.: e 202, excipiens annuncio suspensionem pro dosi. dosi pro vaso 120. - la rinite - synthetika